Last reviewed · How we verify
NCT04536103: MVMS_MRI
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
trial testing MRI in Bone Diseases, Infectious in 88 participants. Currently enrolling.
24 February 2026
Quick facts
| Lead sponsor | Xiaojuan Li |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 88 |
| Start date | 1 April 2022 |
| Primary completion | 24 February 2026 |
| Estimated completion | 28 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- MRI — full drug profile →
Conditions studied
- Bone Diseases, Infectious — all drugs for Bone Diseases, Infectious →
- Musculoskeletal Diseases — all drugs for Musculoskeletal Diseases →
- Joint Diseases — all drugs for Joint Diseases →
- Osteoarthritis — all drugs for Osteoarthritis →
Sponsor
Xiaojuan Li
Who can join
Adults 18 to 50, any sex, with Bone Diseases, Infectious or Musculoskeletal Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Currently the diagnosis of OA is based on radiographs and clinical findings, which is limited to detecting late-stage disease. There is a pressing, unmet clinical need for robust assessment of early changes in cartilage health. Towards this goal, extensive efforts are ongoing to develop quantitative MRI for cartilage matrix analysis. MR T1ρ and T2 relaxation times have shown to be promising imaging biomarkers for early cartilage degeneration and prediction of disease progression. However, many challenges remain to clinically applying these techniques, including lack of standardized acquisition and quantification methods, and long acquisition times. The study aims to develop novel, fast and reproducible MR T1ρ and T2 relaxation time imaging methods on MR systems from multiple vendors and establish a platform for standardization and cross validation of these measures as a tool for clinical trials using such techniques. Following method validation, patients at risk for osteoarthritis will be tested.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04536103
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MRI
Trials testing the same drug.
- NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI · recruiting
- NCT07487870 — Radiographic Evaluation of Tumor Biology During Neoadjuvant Radiotherapy for Sarcoma · NA · not yet recruiting
- NCT07567053 — Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Cerebral Palsy: TMS-EEG Study · NA · not yet recruiting
- NCT07537504 — Language Function Reorganization in Patients With Arteriovenous Malformations · not yet recruiting
- NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
Other recruiting trials for Bone Diseases, Infectious
Currently open trials in the same condition.
- NCT05610098 — Gene Expression Profiles in Spinal Tuberculosis. · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04536103 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiaojuan Li
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04536103.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing